The trial involves around 132 healthy subjects with head lice infestation, 2 years of age and older, in two study centers in the US.
DeOvo, a topical formulation of a known metalloprotease inhibitor, has shown both ovicidal and lousicidal activity and offered the potential for a more effective treatment following a single application.
Hatchtech chairman Paul Kelly said they continue to be encouraged by Hatchtech’s progress with its next generation head lice product DeOvo in line with their business objectives. T
"he recruitment and treatment of subjects in this study has been achieved and we look forward to receiving results of the study later this year as planned," Kelly said.